Siegel R.L. Miller K.D. Jemal A.

Cancer statistics, 2020.

CA Cancer J Clin. 70: 7-30Rahib L. Wehner M.R. Matrisian L.M. et al.

Estimated projection of US cancer incidence and death to 2040.

JAMA Netw Open. 4: e214708Iacobuzio-Donahue C.A. Fu B. Yachida S. et al.

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

J Clin Oncol. 27: 1806-1813Ducreux M. Cuhna A.S. Caramella C. et al.

Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 26: v56-v68Tempero M.A. Malafa M.P. Al-Hawary M. et al.

Pancreatic adenocarcinoma, Version 2.2021, NCCN clinical practice guidelines in oncology.

J Natl Compr Cancer Netw. 19: 439-457

Prognostic indicators for survival after resection of pancreatic adenocarcinoma.

Am J Surg. 165: 68-72

NCCN. Pancreatic adenocarcinoma (Version 2.2021), Available at: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf, 2021. Accessed September 1, 2022.

Kalser M.H. Ellenberg S.S.

Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.

Arch Surg. 120: 899-903Klinkenbijl J.H. Jeekel J. Sahmoud T. et al.

Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Ann Surg. 230 (): 776-782Smeenk H.G. van Eijck C.H. Hop W.C. et al.

Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891.

Ann Surg. 246: 734-740Neoptolemos J.P. Dunn J.A. Stocken D.D. et al.

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.

Lancet. 358: 1576-1585Neoptolemos J.P. Stocken D.D. Friess H. et al.

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

N Engl J Med. 350: 1200-1210Stocken D.D. Buchler M.W. Dervenis C. et al.

Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer.

Br J Cancer. 92: 1372-1381Regine W.F. Winter K.A. Abrams R. et al.

Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the US Intergroup/RTOG 9704 phase III trial.

Ann Surg Oncol. 18: 1319-1326Abrams R.A. Winter K.A. Regine W.F. et al.

Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.

Int J Radiat Oncol Biol Phys. 82: 809-816Berger A.C. Garcia M. Hoffman J.P. et al.

Postresection CA 19-9 Predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704.

J Clin Oncol. 26: 5918-5922Hong T.S. Ryan D.P. Borger D.R. et al.

A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.

Int J Radiat Oncol Biol Phys. 89: 830-838Gillen S. Schuster T. Meyer Z. Buschenfelde C. et al.

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

PLoS Med. 7: e1000267Katz M.H. Pisters P.W. Evans D.B. et al.

Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

J Am Coll Surg. 206 (): 833-846Versteijne E. Suker M. Groothuis K. et al.

Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial.

J Clin Oncol. 38: 1763-1773Versteijne E. van Dam J.L. Suker M. et al.

Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized PREOPANC trial.

J Clin Oncol. 40: 1220-1230Janssen Q.P. van Dam J.L. Bonsing B.A. et al.

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.

BMC Cancer. 21: 300Jang J.Y. Han Y. Lee H. et al.

Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial.

Ann Surg. 268: 215-222Katz M.H.G. Shi Q. Meyers J.P. et al.

Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.

J Clin Oncol. 39: 377Murphy J.E. Wo J.Y. Ryan D.P. et al.

Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial.

JAMA Oncol. 4: 963-969Hammel P. Huguet F. van Laethem J.L. et al.

Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial.

JAMA. 315: 1844-1853Fietkau R. Ghadimi M. Grützmann R. et al.

Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.

J Clin Oncol. 40: 4008Koong A.C. Le Q.T. Ho A. et al.

Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer.

Int J Radiat Oncol Biol Phys. 58: 1017-1021Park C. Papiez L. Zhang S. et al.

Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy.

Int J Radiat Oncol Biol Phys. 70: 847-852Pollom E.L. Alagappan M. von Eyben R. et al.

Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity.

Int J Radiat Oncol Biol Phys. 90: 918-925Song Y.C. Yuan Z.Y. Li F.T. et al.

Analysis of clinical efficacy of CyberKnife (R) treatment for locally advanced pancreatic cancer.

OncoTargets Ther. 8Ryan J.F. Rosati L.M. Groot V.P. et al.

Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients.

Oncotarget. 9: 16427-16436Mellon E.A. Hoffe S.E. Springett G.M. et al.

Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.

Acta Oncol. 54: 979-985Jung J. Yoon S.M. Park J.H. et al.

Stereotactic body radiation therapy for locally advanced pancreatic cancer.

PLoS One. 14: e0214970Arcelli A. Guido A. Buwenge M. et al.

Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: a multicentric analysis (PAULA-1).

Anticancer Res. 40: 465-472Oar A. Lee M. Le H. et al.

AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.

BMC Cancer. 21Wang R.C. Goepfert H. Barber A.E. et al.

Unknown primary squamous cell carcinoma metastatic to the neck.

Arch Otolaryngol Head Neck Surg. 116: 1388-1393Brunner T.B. Haustermans K. Huguet F. et al.

ESTRO ACROP guidelines for target volume definition in pancreatic cancer.

Radiother Oncol. 154: 60-69Oar A. Lee M. Le H. et al.

Australasian gastrointestinal trials group (AGITG) and trans-tasman radiation oncology group (TROG) guidelines for pancreatic stereotactic body radiation therapy (SBRT).

Pract Radiat Oncol. 10: e136-e146Palta M. Godfrey D. Goodman K.A. et al.

Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline.

Pract Radiat Oncol. 9: 322-332Brunner T.B. Merkel S. Grabenbauer G.G. et al.

Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis.

Int J Radiat Oncol Biol Phys. 62: 1021-1029Kharofa J. Mierzwa M. Olowokure O. et al.

Pattern of marginal local failure in a phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer.

Am J Clin Oncol. 42: 247-252Zhu X. Ju X. Cao Y. et al.

Patterns of local failure after stereotactic body radiation therapy and sequential chemotherapy as initial treatment for pancreatic cancer: implications of target volume design.

Int J Radiat Oncol Biol Phys. 104: 101-110Miller J.A. Toesca D.A.S. Baclay J.R.M. et al.

Pancreatic stereotactic body radiation therapy with or without hypofractionated elective nodal irradiation.

Int J Radiat Oncol Biol Phys. 112: 131-142Elhammali A. Patel M. Weinberg B. et al.

Late gastrointestinal tissue effects after hypofractionated radiation therapy of the pancreas.

Radiat Oncol. 10: 186Heerkens H.D. van Vulpen M. van den Berg C.A. et al.

MRI-based tumor motion characterization and gating schemes for radiation therapy of pancreatic cancer.

Radiother Oncol. 111: 252-257Bohoudi O. Bruynzeel A.M.E. Senan S. et al.

Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer.

Radiother Oncol. 125: 439-444Henke L. Kashani R. Robinson C. et al.

Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen.

Radiother Oncol. 126: 519-526Rudra S. Jiang N. Rosenberg S.A. et al.

Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer.

Cancer Med. 8: 2123-2132Chuong M.D. Bryant J. Mittauer K.E. et al.

Ablative 5-fraction stereotactic magnetic resonance-guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer.

Pract Radiat Oncol. 11: 134-147Hassanzadeh C. Rudra S. Bommireddy A. et al.

Ablative five-fraction stereotactic body radiation therapy for inoperable pancreatic cancer using online MR-guided adaptation.

Adv Radiat Oncol. 6: 100506Hall W.A. Small C. Paulson E. et al.

Magnetic resonance guided radiation therapy for pancreatic adenocarcinoma, advantages, challenges, current approaches, and future directions.

Front Oncol. 11: 628155Chuong M.D. Kirsch C. Herrera R. et al.

Long-term multi-institutional outcomes of 5-fraction ablative stereotactic mr-guided adaptive radiation therapy (SMART) for inoperable pancreas cancer with median prescribed biologically effective dose of 100 Gy10</sub>.

Int J Radiat Oncol Biol Phys. 111: S147-S148Perone J.A. Riall T.S. Olino K.

Palliative care for pancreatic and periampullary cancer.

Surg Clin North Am. 96: 1415-1430Ebrahimi G. Rasch C.R.N. van Tienhoven G.

Pain relief after a short course of palliative radiotherapy in pancreatic cancer, the Academic Medical Center (AMC) experience.

Acta Oncol. 57: 697-700Buwenge M. Macchia G. Arcelli A. et al.

Stereotactic radiotherapy of pancreatic cancer: a systematic review on pain relief.

J Pain Res. 11: 2169-2178Hammer L. Hausner D. Ben-Ayun M. et al.

Single-fraction celiac plexus radiosurgery: a preliminary proof-of-concept phase 2 clinical trial.

Int J Radiat Oncol Biol Phys. 113: 588-593Hoyer M. Roed H. Sengelov L. et al.

Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma.

Radiother Oncol. 76: 48-53Weichselbaum R.R. Hellman S.

Oligometastases revisited.

Nat Rev Clin Oncol. 8: 378-382Hagiwara K. Harimoto N. Araki K. et al.

Long-term survival of two patients with pancreatic cancer after resection of liver and lung oligometastases: a case report.

Surg Case Rep. 6: 309Saedon M. Maroulis I. Brooks A. et al.

Metastasectomy of pancreatic and periampullary adenocarcinoma to solid organ: The current evidence.

J BUON. 23: 1648-1654Yachida S. Jones S. Bozic I. et al.

Distant metastasis occurs late during the genetic evolution of pancreatic cancer.

Nature. 467: 1114-1117Yamanaka M. Hayashi M. Yamada S. et al.

A possible definition of oligometastasis in pancreatic cancer and associated survival outcomes.

Anticancer Res. 41: 3933-3940Elamir A.M. Karalis J.D. Sanford N.N. et al.

Ablative radiation therapy in oligometastatic pancreatic cancer to delay polyprogression, limit chemotherapy, and improve outcomes.

Int J Radiat Oncol Biol Phys. 114: 792-802